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Interventional ablative technologies have played an increasingly important role in the management of patients with primary or secondary
liver malignancies. Ethanol and acetic acid ablation were the primary modalities available 2 decades ago. Today, several new technologies are
available, including radiofrequency ablation, cryoablation, and microwave ablation. Radiofrequency ablation is the most widely practiced,
however, cryoablation and microwave ablation are reasonable choices in certain situations. Irreversible electroporation is a newer technique,
which has yet to enter clinical practice, but shows promising preliminary results. Herein, we provide a brief overview of the above-mentioned
technologies with a focus on principles of ablation and technique. We also describe the use of these techniques in the context of cytor-
eduction, a noncurative approach aimed at reducing the overall tumour burden and providing concomitant survival benefit.Re´sume´
Les technologies d’ablation interventionnelles (percutane´es) jouent un roˆle de plus en plus important dans la gestion des patients atteints
d’un cancer primitif ou secondaire du foie. L’ablation a` l’e´thanol et a` l’acide ace´tique ont e´te´ les premie`res techniques utilise´es il y a deux
de´cennies. Aujourd’hui, plusieurs nouvelles technologies sont disponibles, dont l’ablation par radiofre´quence, la cryo-ablation et l’ablation
par micro-ondes. L’ablation par radiofre´quence est la technique la plus couramment utilise´e, mais la cryo-ablation et l’ablation par micro-
ondes se re´ve`lent des choix sense´s dans certaines situations. L’e´lectroporation irre´versible est une technique plus re´cente qui n’est pas encore
utilise´e en pratique clinique, mais dont les re´sultats pre´liminaires sont prometteurs. Le pre´sent article fournit un bref aperc¸u des technologies
mentionne´es ci-dessus en mettant l’accent sur les principes d’ablation et la technique utilise´e. Il de´crit e´galement l’utilisation des techniques
en cytore´duction, une approche novatrice visant a` re´duire le fardeau tumoral global et a` produire un avantage concomitant de survie.
 2010 Canadian Association of Radiologists. All rights reserved.
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carcinoma (HCC), continues to rise, and it is now the fifth
most common cancer in the world. This is primarily related
to the increase in the prevalence of chronic hepatitis B and C
viral infections worldwide [1]. Currently, HCC is primarily* Address for correspondence: Dave M. Liu, MD, Department of Radi-
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doi:10.1016/j.carj.2009.12.009a surgically managed disease process, either through resec-
tion or transplantation [2].
Because of limitations in organ allocation, costs, and the
high rates of clinical ineligibility (‘‘Milan’’ and University of
California San Francisco [‘‘UCSF’’] criteria), many patients
fail to undergo transplantation. Surgical resection serves as the
next best alternative, either as a bridge to transplantation or as
a primary treatment modality. However, a substantial propor-
tion of patients are precluded from surgical options because of
a lack of hepatic reserve, extrahepatic disease, and comorbidll rights reserved.
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neous ablation, have taken on a greater role in the management
of patients with primary liver cancer who are unable to benefit
from liver transplantation or surgical resection.
In addition to primary hepatic malignancies, the liver is
a frequent site for metastatic spread of tumour from distant
primary sites, including colorectal, neuroendocrine, breast,
and a host of other primary malignancies [4]. In patients with
metastatic liver disease, bilobar, nonresectable disease is
common, and this presents unique challenges in the overall
management of these patients. Today, a variety of options
exist for these patients in the context of locoregional therapy,
including surgical resection [5], systemic or hepatic artery
chemotherapy [6,7], and various ablative technologies [8,9].
Patients often undergo a combination of these therapeutic
modalities in an effort to apply a patient-centered, evidence-
based approach to therapy.
The objective of this article is to provide a brief overview of
the various ablative technologies available in the management
of patients with primary and secondary liver malignancies,
including chemical ablation (ethanol and acetic acid), radio-
frequency ablation (RFA), cryoablation, microwave ablation,
and irreversible electroporation (IRE). We also describe the
use of these techniques in the context of cytoreduction,
a noncurative approach aimed at reducing the overall tumour
burden while providing concomitant survival benefit.
Overview of Ablative TechnologiesChemical Ablation (Ethanol and Acetic Acid)Figure 1. Representative, coronal, contrast-enhanced computed tomography
images through the upper abdomen in a patient with metastatic liver disease.
(A) Preablation image shows a well-demarcated, subscapular (arrows) lesion
within the liver. (B) Image that demonstrates the tip of the radiofrequency
electrode (arrow), with multiple metal tines situated within this lesion.Chemical ablation, which involves the use of absolute
ethanol or acetic acid, is the oldest of the ablative technolo-
gies. In patients with small HCC, ethanol ablation was shown
to be an effective treatment modality [10,11]. However, the
role of chemical ablation in patients with metastatic disease is
limited, because alcohol tends to spread preferentially into
the surrounding ‘‘soft’’ liver parenchyma as opposed to
remaining within the higher density tumour mass [12].
The technique for percutaneous ethanol injection (PEI) is
similar whether used in the treatment of HCC or liver
metastasis. The mechanism of action of ethanol and acetic
acid ablation includes cellular dehydration, coagulative
necrosis, protein denaturation, and small-vessel thrombosis of
the target lesion [13]. The low viscosity and limited ability to
control the distribution has remained a fundamental limita-
tion. PEI can be performed under ultrasound or computed
tomography guidance with monitored moderate sedation.
Typically, a 20e22-gauge end-hole needle (Chiba) or conical
tip needle is used, more recently, 18-gauge multisided hole
needles were advocated [14]. Small lesions can be
approached by placing the needle at the most-distal aspect of
the lesion with injection of ethanol during retraction, whereas
larger tumours require multiple repositionings of the needle,
insertion of multiple needles, and/or multiple sessions. This
procedure is usually well tolerated by patients, with a repor-
ted incidence of complications, less than 5% [15,16].In addition to PEI, percutaneous acetic acid injection
(PAI) with 50% acetic acid is another available option. The
primary advantage with PAI is that the solution is able to
penetrate the septae and the capsule of tumours, and, hence,
a lower amount of acetic acid and fewer overall sessions are
needed compared with PEI to achieve the same results [17].
Otherwise, the technique is similar to that of PEI. Overall,
both PEI and PAI are safe, easy to perform procedures but
with limited indications because of the limitations in size and
site of treatable lesions, unpredictability of agent diffusion,
and the inability to monitor the treatment area. Thus, PEI and
PAI have been surpassed by newer ablative techniques, such
as RFA and cryoablation.RFARFA is the most widely practiced ablative technology and
is used in the management of patients with both primary and
metastatic liver disease. RFA relies on the generation of
high-frequency, alternating electrical currents within the
target tissues, which results in ionic agitation. The frictional
forces lead to the generation of heat, which, in turn, results in
thrombosis, thermally induced necrosis, protein denaturing,
dehydration, coagulative necrosis, and apoptosis [18].
Because of the small surface area of the needle electrode and
the large area of the ground pads, the heat generated is
focused in the area around the needle [19], with the amount
of cell damage induced dependent on the temperature ach-
ieved and the duration of treatment. The goal in RFA is to
achieve target tissue temperatures of between 50Ce100C
for 4e6 minutes, because this results in optimal cellular
necrosis and death [20].
Figure 2. Sonographic images of the liver in a patient with hepatocellular carcinoma taken preradiofrequency (A, B) and postradiofrequency (C) ablation.
(A, B) Images that demonstrate a heterogeneous, hypoechoic nodule in segment 7 of the liver (arrows), biopsy proven to be hepatocellular carcinoma.
(C) Posteradiofrequency ablation image shows marked increase in echogenicity in the same region (arrow), with minimum posterior dirty shadowing,
consistent with gas and coagulation necrosis.
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nology is the idea of heat efficacy, which is defined as the
difference between the amount of heat energy deposited and
the amount lost to surrounding nontumour structures. Recent
advances in radiofrequency ablation (RFA) technology have
focused on maximizing the amount of heat deposited in
tissues, minimizing the amount of heat lost to surrounding
structures, and minimizing the rate of desiccation of the
ablated tissue, to maintain conductivity. Some strategies have
included increasing the RF output of generators to 150e250
W, infusion of ionic solutions, use of internally cooled elec-
trodes, multiple or multitined expandable electrodes,
monopolar systems that decrease impedance, and complex
algorithms that control various parameters, including
temperature [20,21]. A recent breakthrough in RF technology
was the advent of bipolar RFA needles (previous needles were
monopolar). These needles have the potential to deliver a more
defined and uniform energy to the target tissue confined
between the 2 electrodes, without the need for grounding pads
and also decreasing the overall impedance of the RF circuit
[22]. The use of bipolar devices and modifications designed to
maximize heat transfer have resulted in larger and more reli-
able zones of ablation in the target tissue (Figures 1 and 2).Microwave AblationFigure 3. Representative sonographic (A) and computed tomography (B)
images of the liver in a patient with metastatic endometrial cancer who
developed recurrent metastases in segments 2 and 3 of her liver. (A) Image
shows the appearance of the liver before microwave ablation. (B) Post-
ablation image with a triple antenna approach shows the well-circumcised
zone of ablation (arrows). (Images courtesy of Dr Justin McWilliams and
Dr David Lu, UCLA Medical Center.)Microwave ablation is another heat-based ablation tech-
nology available in the management of patients with unre-
sectable liver tumours. Microwave energy emanates from the
feed point of the radiating section of an antenna to cause
tissue coagulation [23]. Microwave energy creates heat by
generating friction through agitation of water molecules, an
inherently different mechanism of action than RFA tech-
nology. With microwave ablation, there is no current flow
through the patient, which obviates the need for grounding
pads [24]. More recently, the use of synchronous triple
antennas has been proposed, which allow for much larger
ablation zones within shorter periods of time (Figure 3) [25].
Currently, there is only 1 commercially available, Food and
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marketed by Covidien (Boulder, CO), the Evident micro-
wave ablation system, which was launched in 2008 [26].CryoablationCryoablation is an established ablation technique that is
fundamentally different from the heat-based RFA and
microwave ablation technologies. The technique itself
involves rapid freezing of the tissues to temperatures below
0C, which results in intra- and extracellular ice crystal
formation and cellular damage by dehydration and destruc-
tion of normal cellular architecture [24]. Liquid nitrogen was
used as the initial cryogen; however, this limited the tech-
nology to the operative setting because the probe sizes were
too large (in excess of 7 mm) [27]. The introduction of argon
gas based systems and smaller probe sizes that use the
Joules-Thompson effect (with probes as small as 17 gauge)
has made percutaneous use feasible [27].
In cryoablation, the number and placement of the probes is
dependent on the tumour size. The ‘‘2 to 1’’ rule [28] outlines
that multiple cryoprobes can be placed within 1 cm of the
tumour edge, and there should not be more than a 2-cm gap
between the probes. This configuration allows for synergistic
achievement of target temperatures and maximal zones of cell
death, ideal in targeting large tumour masses and/or multiple
tumour masses concomitantly. The ability to place multiple
probes simultaneously is one potential advantage of cryoa-
blation, because multiple probes may allow for the creation of
larger, synergistic zones of ablation compared with RFA in the
treatment of large hepatic masses (Figure 4) [27].IREIRE is a novel, nonthermal ablation technology that has
yet to enter clinical practice. However, early in vitro and inFigure 4. Representative, axial, contrast-enhanced computed tomography images
hepatocellular carcinoma. (A) Image that demonstrates a large hypoattenuating,
enhancement. (B) Image shows the zone of ablation (arrows) after cryoablation.vivo studies show promising results [29,30]. In IRE, micro-
to millisecond electrical pulses are delivered to the target
tissue to induce permanent cell membrane permeability and
cell death, with no effect on the surrounding cell structures
[31]. Studies demonstrated complete hepatocyte cell death in
the ablation zone, with a narrow transition between the
ablation zone and the surrounding uninjured tissue [30]. The
ability to monitor this process with real-time ultrasound
imaging makes it potentially useful in clinical practice
(Figure 5). IRE has the potential to be an effective
nonthermal ablative option for patients in whom the tumour
anatomy makes it difficult for them to undergo traditional
thermal-based RFA or microwave ablation.Cytoreductive Therapy
In patients with advanced primary and secondary liver
cancer, cytoreductive therapy, a noncurative intervention
aimed at reducing the overall tumour burden, can signifi-
cantly reduce symptoms and patient morbidity. This can be
achieved with either surgical resection and/or the use of
various ablative technologies as described above and has
been most studied in patients with HCC [32], liver metas-
tases from colorectal cancer [33], and neuroendocrine cancer
[34].
Patients with recurrence of their HCC have a median
survival from time of recurrence of less than 12 months.
Covey et al [32] showed that bland arterial embolization was
an effective salvage therapy in patients with recurrent HCC
with prior surgical resection, which demonstrates median
survival of 46 months from the time of recurrence. In patients
with advanced HCC, Lai et al [35] showed that overall 3-year
survival was significantly better in the cytoreductive group
than the palliative group (54% vs 22%), with a median
survival of 18 and 11 months in the 2 groups, respectively.
Together, these studies support that patients with recurrent orthrough the liver taken pre- (A) and postcryoablation (B) in a patient with
hypovascular region (arrow) within segment 7 of the liver with peripheral
Figure 5. Sonographic images through the liver in a swine model, before (A) and after (B) irreversible electroporation (IRE) embolization. (A) Image
demonstrates the positioning of the probes (arrows). (B) Post-IRE image shows the hypoechoic ablation zone (arrows). (Images courtesy of Dr Edward W. Lee,
UCLA Medical Center.)
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from further cytoreductive measures.
Patients with liver metastases from colorectal cancer often
develop recurrence of their liver metastases after surgical
resection. In these patients, repeated hepatic resection was
shown to improve survival [36,37]. Results of other studies
have supported a role for surgery after downstaging of the
initial unresectable liver tumours with various forms of
chemotherapy, including intra-arterial chemotherapy [38]. In
selected patients with advanced, extrahepatic disease, liver
resection has also been shown to increase survival, which
disputes the earlier notion that extrahepatic disease should be
an absolute contraindication for liver resection in these
patients [39]. Substituting surgical resection with invasive
percutaneous RFA in the treatment of hepatic colorectal
carcinoma liver metastases may also provide a survival
benefit [40].
Finally, in patients with hepatic neuroendocrine meta-
static disease, cytoreductive therapies can play a major role
in helping to reduce the degree of symptomatic endo-
crinopathies. McEntee et al [34] found that cytoreductive
hepatic surgery produced complete relief of symptoms in 24
of 26 patients who were symptomatic either from the
primary tumour or an associated endocrinopathy. More
recently, the National Comprehensive Cancer Network
published its guidelines and outlined the role of various
ablation technologies in the overall management of patients
with liver metastases from advanced primary neuroendocrine
tumours [41].
Summary
Interventional ablative technologies have played an
increasingly important role in the optimal management of
patients with primary and secondary hepatic malignancies.
RFA is the most widely practiced of the ablative technolo-
gies; however, other options, such as microwave ablation or
cryoablation, are also available. IRE is a relatively new
ablative technology that will likely soon enter clinicalpractice and offer another option to the interventional radi-
ologist. In addition to their role as first- and second-line
treatment options, recent studies have also expanded the
role of these technologies as cytoreductive therapies in
patients with noncurative, advanced disease. Cytoreductive
ablation can reduce overall disease burden and improve
morbidity.
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